Bullous pemphigoid and diabetes mellitus: Are we missing the larger picture?

To the Editor: We read with interest the study by Benzaquen et al1 reporting an increased risk for development of bullous pemphigoid (BP) in patients who are receiving a dipeptidyl peptidase-4 inhibitor (DPP4i). Their findings are supported by previous studies showing a significant signal of increased risk for development of BP during exposure to a DPP4i in the European and French pharmacovigilance databases.1